Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 21, 2026.

Research Status and Molecular Mechanism of the Traditional Chinese Medicine and Antitumor Therapy Combined Strategy Based on Tumor Microenvironment

Yang Zhang, Yanni Lou, Jingbin Wang and 2 more (opens in a new tab)

Frontiers in Immunology · 2021 · Review · CC BY

doi:10.3389/fimmu.2020.609705 (opens in a new tab)

Abstract

Treatment of malignant tumors encompasses multidisciplinary comprehensive diagnosis and treatment and reasonable combination and arrangement of multidisciplinary treatment, which is not a simple superimposition of multiple treatment methods, but a comprehensive consideration of the characteristics and specific conditions of the patients and the tumor. The mechanism of tumor elimination by restoring the body’s immune ability is consistent with the concept of “nourishing positive accumulation and eliminating cancer by itself” in traditional Chinese medicine (TCM). The formation and dynamic changes in the tumor microenvironment (TME) involve many different types of cells and multiple signaling pathways. Those changes are similar to the multitarget and bidirectional regulation of immunity by TCM. Discussing the relationship and mutual influence of TCM and antitumor therapy on the TME is a current research hotspot. TCM has been applied in the treatment of more than 70% of cancer patients in China. Data have shown that TCM can significantly enhance the sensitivity to chemotherapeutic drugs, enhance tumor-suppressing effects, and significantly improve cancer-related fatigue, bone marrow suppression, and other adverse reactions. TCM treatments include the application of Chinese medicine monomers, extracts, classic traditional compound prescriptions, listed compound drugs, self-made compound prescriptions, as well as acupuncture and moxibustion. Studies have shown that the TCM functional mechanism related to the positive regulation of cytotoxic T cells, natural killer cells, dendritic cells, and interleukin-12, while negatively regulating of regulatory T cells, tumor-associated macrophages, myeloid-derived suppressive cells, PD-1/PD-L1, and other immune regulatory factors. However, the application of TCM in cancer therapy needs further study and confirmation. This article summarizes the existing research on the molecular mechanism of TCM regulation of the TME and provides a theoretical basis for further screening of the predominant population. Moreover, it predicts the effects of the combination of TCM and antitumor therapy and proposes further developments in clinical practice to optimize the combined strategy.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Cancer is one of the major noncommunicable chronic diseases that seriously affect human health. Although treatment methods and drug research and development continue to improve, many problems such as drug resistance and recurrence still hinder progress. The treatment of malignant tumors encompasses multidisciplinary comprehensive diagnosis and treatment and reasonable combination and arrangement of multiple treatment methods including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, endocrine therapy, interventional therapy. Multidisciplinary treatment is not a simple superimposition of multiple treatment methods, but a comprehensive consideration of the characteristics and specific conditions of the patients and the tumor, leading to a planned and reasonable choice. While pursuing prolonged survival, attention should also be given to improving the quality of life of the patients.

Due to its huge population, China accounts for about a quarter of the world’s new tumors and deaths, leading to a serious disease burden. Traditional Chinese medicine (TCM) is a unique diagnosis and treatment method with thousands of years of history. It is reported that most Chinese cancer patients have used TCM during the diagnosis and treatment process. TCM is mostly used in the form of compound prescriptions in clinical oncology, including oral herbal medicines, granules or capsules, and injections. There are many pieces of research on Chinese medicine monomers and their active ingredients. Many researches have shown that TCM combined with antitumor therapy can achieve significant tumor suppression effects, reduce drug resistance, and improve adverse reactions and patient quality of life. In recent years, targeting the immune checkpoints CTLA-4, PD-1, and PD-L1 has led to breakthroughs in a variety of cancer types. The mechanism of tumor eradication by restoring the body’s immune ability is consistent with the concept of “nourishing positive accumulation and eliminating cancer by itself” or “strengthening vital Qi to treat cancer” in TCM.

The tumor microenvironment (TME) is formed by the structural components such as tumor cells, endothelial cells, fibroblasts, immune cells, extracellular matrix, and secreted cytokines. It has three main roles: inhibiting the immune response, promoting angiogenesis, and growing cancer stem cells. Chronic inflammation and immunosuppression are the core features of the TME. Chronic inflammation leads to low oxygen levels, low pH, high pressure in the microenvironment, and the prolonged existence of inflammatory factors such as tumor necrosis factor (TNF) that maintain and continuously aggravate the inflammatory features of the TME. The hypoxic microenvironment increases hypoxia inducible factor (HIF) levels, induces the formation of new blood vessels, modifies the vascular endothelial growth factor (VEGF), and recruits bone marrow-derived endothelial progenitor cells to form new blood vessels. The TME enables a large number of regulatory T cells (Tregs) that penetrate and accumulate in tumor tissues, inhibit the differentiation and maturation of effector cells such as lymphocytes, macrophages, dendritic cells (DC), and isolate them from tumor tissues to inhibit immune responses. The immunosuppressive microenvironment is closely related to the “deficiency of vital Qi” in Chinese medicine. The “syndrome” of TCM involves multiple systems and levels of Western medicine. TCM treatment of cancer pays attention to overall regulation whether it is to strengthen the body (Fu Zheng) or eliminate evil (Qu Xie). Its advantage lies in regulating the tumor-host microenvironment, allowing normal immune cells to perform their duties, so that there is no environment for tumor cells to survive, and causing apoptosis or autophagy.

In this review, we mainly discuss, from the perspective of TME regulation, the studies on the combined application of TCM and anticancer treatments. Further screening of dominant populations and predictors will help optimize the joint strategy and provide a theoretical basis for clinical practice.

TCM Combined With Chemotherapy

Chemotherapy is still the cornerstone of anticancer therapy. As one of the most important treatments for advanced stage cancer, chemotherapy compatibility ensures the correct combination of chemotherapeutic drugs and the combination of chemotherapy and other types of treatment. There are many clinical and preclinical studies on the combination of TCM treatment and chemotherapy.

The clinical studies on TCM combined with chemotherapy for anticancer treatment research have been mainly published in Chinese journals ( Table 1 ). The studied cancer types include lung cancer, digestive system cancer (gastric/liver/esophageal cancer), gynecological cancer (ovarian cancer, choriocarcinoma, breast cancer), and bladder cancer. The observed drugs are mainly compound herbal medicines, including classic prescriptions [Baihe Gujin decoction, Yanghe decoction], listed drugs [Shenqi Fuzheng injection, Kanglaite injection, compound Kushen injection, Aidi injection, Jinfukang oral liquid, Yifei Qinghua granules], a variety of self-made empirical formulas, and monomeric Chinese medicines or their components (matrine). The results consistently show that TCM can help improve the sensitivity to chemotherapeutic drugs, enhance tumor-suppressing effects, and significantly improve cancer-related fatigue, bone marrow suppression, and other adverse reactions. The quality of life self-report scores also show significant improvement. Regarding the regulation of tumor immune function, clinical studies mainly detected immune-related factors in peripheral blood. The results concluded that TCM combined with chemotherapy can upregulate CD3+, CD4+, and CD4+/CD8+, interleukin-2 (IL-2), interferon-gamma (INF-γ), natural killer cells (NK), and cytotoxic T lymphocytes (CTL), while downregulating IL-6, IL-10, transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor(VEGF), matrix metalloproteinase-2 (MMP-2), MMP-9, Forkhead box protein 3 (Foxp3), and B7-H3, and Tregs. However, there are also inconsistencies between different research results for some indicators.

Experimental studies were conducted through in vivo and in vitro research ( Table 2 ). Cell and animal experiments present more in-depth research on the mechanism of TCM improvement of chemotherapeutic efficacy. The observed drugs include Chinese medicine monomers [curcumin, ginsenoside Rg3], extracts [Ginseng and Astragalus], classic traditional compound prescriptions [Huangqin decoction PHY906, Shiquan Dabu decoction], listed compound drugs [Shexiang Baoxin pill], and self-made compound prescriptions. The most representative ones are curcumin, PHY906, and tonic Chinese medicines. The combination of curcumin and chemotherapy has been proven to overcome multidrug resistance [FOLFOX, oxaliplatin, 5-Fu] through a number of in vivo and in vitro studies. The effect of this combined therapy may upregulate Bax, caspase-3, and PARP and downregulate EGFRs (such as IGF-1R), Bcl‐2, survivin, HSP70, Nrf2, Bcl-2/Bax, NF-κB, p-p65, and TGF-β/Smad2/3. PHY906 is derived from the classic formula prescription Huangqin decoction; however, instead of the separation and purification of the possible active compounds, it is taken as a whole. In-depth research via animal experiments, clinical trials, and quality control of PHY906 have been conducted. Results showed that PHY906 could significantly increase the antitumor activity of CPT-11, decreasing toxicity in normal tissues while promoting cell death within the TME, and that its effect may be upregulated by IRF-1, IRF-5, CCL-2/MCP-1, and CCL-5/RANTES. Tonic Chinese medicines include monomers, water extracts, the classic compound Shiquan Dabu decoction, or self-made prescriptions, and their mechanism of action may be related to the regulation of macrophage polarization, the reduction of epithelial cell-mesenchymal transition, and cell stemness.

TCM Combined With Targeted Therapy or Immunotherapy

Unlike the destructive antitumor effects of traditional chemotherapy, new molecular targeted therapies target specific molecular changes in cancer. They have achieved significant effects in clinical practice in recent years and have also triggered a change in the concept of anticancer treatment. The immunotherapeutic approach involves the restart and maintenance of the tumor immune cycle, the restoration of the body’s normal antitumor immune response, and the control and elimination of cancer, by means such as monoclonal antibody immune checkpoint inhibitors, therapeutic antibodies, tumor vaccines, cell therapy, and small molecule inhibitors. Among them, PD-1 inhibitors lead the treatment of malignant tumors into a new era of immunotherapy. There are currently many studies on the combined application of TCM and targeted drugs or immunotherapy, focusing on improving efficacy, reversing drug resistance, and reducing adverse reactions. Some research results describing the impact of TCM combined with targeted drugs ( Table 3 ) and immunotherapy ( Table 4 ) on the TME have been released; however, there are still more treatment aspects that need further clarification.

In addition to evaluating the immune function of peripheral blood, some studies involved the detection of tumor-specific markers and tumor tissue-related factors to evaluate the invasion ability of tumors. Clinical studies on non-small-cell lung carcinoma (NSCLC), hepatocellular carcinoma, and ovarian cancer use compound preparations, including classic traditional formula Xuefu Zhuyu decoction and listed compound herbal medicine Shenqi Fuzheng injection. During in vitro and in vivo studies, apart from observing the effects on tumor cell proliferation, the related signaling pathways were explored, including the NF-κB and p38 MAPK signaling cascades mediated by TNFR1 in hepatocellular carcinoma cells (compound Kushen injection) and the AKT pathway in gastric cancer and pancreatic cancer cells (Astragalus polysaccharide). YIV-906, which is based on PHY906, is a clinical observation drug that ensures >90% consistency in product quality. It is also the first Chinese medicinal project to be awarded a grant from the PO1 program of the National Cancer Center of the United States. Animal experiments show that PHY906 may potentiate sorafenib action and that its mechanism of action involves an increase in hMCP1 expression, enhanced infiltration of macrophages into tumors with a higher M1/M2 expression pattern, and upregulation of AMPKα-P and ULK1-S555-P. Computer simulation methods have also been used in the analysis of its mechanism of action and key components.

Whether tonic herbal medicine be used in combination with immunotherapy is one of the issues that Chinese cancer patients are extremely concerned about; moreover, it is a very controversial issue for cancer clinicians. Research on the combination of TCM and immunotherapy mainly includes in vivo and in vitro studies, while clinical studies are rarely conducted. The TCM studied mostly include tonic drugs or their components: Astragalus, ginsenoside Rg3, Glycyrrhiza uralensis water extract, and bisdemethoxycurcumin. Most of the compound prescriptions are classic medicines, including Gegen Qinlian decoction, Renshen Yangrong decoction, Shiquan Dabu decoction, Guipi decoction, and Buzhong Yiqi decoction. The components of Astragalus can downregulate PD-L1 on the tumor cell surface, which may be related to the AKT/mTOR/p70S6K pathway. In vivo studies have shown that TCM combinations have a positive effect on therapeutic curative potential and tumor inhibition. Some studies also explored the intestinal flora; however, in clinical observation, the main observed effect remains the improvement of symptoms. Both TCM treatment and immunotherapy have systematic and complex characteristics. Determining whether TCM affects the efficacy or the adverse effects of immunotherapy by regulating the TME and related factors necessitates further research.

TCM Combined With Local Treatment

Malignant tumors require different treatment strategies according to the different stages of the disease. Additionally, local treatment plays an important role in the treatment of cancer. Early radical surgery is the most effective way to obtain a curative effect and long-term survival. Radiotherapy and interventional therapy can obtain survival benefits and symptom improvement through the control of local lesions. The combined citation of TCM and local treatment have been clinically observed to reduce perioperative complications, promote the recovery of immune function, reduce recurrence and metastasis, and improve long-term prognosis. The TCM involved are mostly listed drugs ( Table 5 ), and research on their mechanism of action is relatively lacking and limited to peripheral blood immune function detection.

Discussion

The clinical application of TCM has a long history, and its treatment principles and philosophy have a unique system. With the continuous improvement of research methods, our understanding of TCM is deepening. The study of herbal medicine monomers and their components is relatively easy to explain; however, compound prescription and compatibility are more characteristic of TCM holistic thinking. TCM has its advantages and specifics in the treatment of cancer. In addition to reducing the side effects of antitumor treatment and improving the symptoms and patient quality of life, it also “supports the healthy Qi” and restores the body’s own immune system. It can improve efficacy and prolong survival in the comprehensive treatment of cancer.

Many studies on the monomers or components of herbal medicine have confirmed that they affect related factors in the TME; however, their effects in a more complex system are relatively unexplored. This review summarizes and analyzes the influence and effect of TCM in combination with antitumor therapy, including chemotherapy, targeted therapy, immunotherapy, the perioperative period, radiotherapy, and interventional therapy. Relevant Chinese medicines include marketed drugs (injections, oral liquids, and tablets), traditional prescriptions, and self-developed experiential prescriptions, as well as many Chinese medicinal monomers or ingredients. Tonic drugs are the main active agents, including multiple treatments such as replenishing Qi, invigorating the spleen, promoting blood circulation, eliminating phlegm, clearing heat, and dispelling stagnation. It is well known that the immune system of body, plays defensive, protective and eliminative roles on tumor cells. For example, NK cells can directly recognize and eradicate tumor cells; Dendritic cells (DCs) can activate adaptive immunity; macrophages (M) can kill tumor cells by generating cytotoxicity, which related to the production of effector molecules and accompanying phagocytosis. Clinical studies have shown that adding TCM to the treatment strategy can significantly improve patient symptoms without increasing adverse reactions, with a tendency to prolong survival. The detection of peripheral blood-related immune factors suggests that TCM has a regulatory effect on immune function and that it can promote a healthy Th1/Th2 balance and regulate the polarization of macrophages. Peripheral blood is the most commonly used medium for disease diagnosis and has been widely accepted by patients for noninvasive molecular diagnosis. In addition, compared with the tumor tissue sample, the dynamic change of microenvironment is ignored, and the peripheral blood can be sampled for many times regularly, which is convenient for monitoring. In relevant in vivo and in vitro studies, possible mechanisms of action have been discussed, including the classical NF-κB, AKT, and TLR4 signaling pathways and the intestinal flora. However, TCM treatment still needs to go through top-level design, good quality control, reverse verification, and in-depth research that can reproduce results to demonstrate the role of TCM in the comprehensive treatment of tumors and clarify its therapeutic mechanism.

Conclusions

Cancer treatment has multiple stages and high complexity, and the optimal approach includes multidisciplinary comprehensive diagnosis and treatment. TCM has its unique advantages and characteristics that are different from other types of antineoplastic treatment, and these should not be ignored. However, current research results cannot clearly explain the dominant population and mechanism of effect of TCM combined with antitumor therapy; however, the impact on the TME may be the core principle of this approach. More evidence-based experimental research is still needed to provide a basis for formulating better combined strategies for cancer treatment.

Author Contributions

YZ, YL, and WS concepted and designed the review. YZ and YL wrote the manuscript. JW, CY, and WS revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work is supported by the National Natural Science Foundation of China (No. 81973601 and No. 81904003), and the Beijing Municipal Natural Science Foundation (No. 7202184).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 104

  1. 1.

    Freddie BBMP JF ME Isabelle Soerjomataram MD MP, MPH RLS, MSPH LAT, Ahmedin Jemal PhD D. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin (2018 ) 68:394–424.

    Not in our library10.3322/caac.21492 (opens in a new tab)

  2. 2.

    Fidler MM Bray F Soerjomataram I The global cancer burden and human development: A review. Scand J Public HEALT (2018 ) 46:27–36.

    Not in our library10.1177/1403494817715400 (opens in a new tab)

  3. 3.

    Camilla M Giuseppe L Cancer statistics: a comparison between World Health Organization (WHO) and Global Burden of Disease (GBD). Eur J Public Health (2019 ) 30:1026–27.

    Not in our library10.1093/eurpub/ckz216 (opens in a new tab)

  4. 4.

    Neil V José B M HD A view on drug resistance in cancer. Nature (2019 ) 575:299–309.

    Not in our library10.1038/s41586-019-1730-1 (opens in a new tab)

  5. 5.

    Nikolaou M Pavlopoulou A Georgakilas AG Kyrodimos E The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastas (2018 ) 35:309–18.

    Not in our library10.1007/s10585-018-9903-0 (opens in a new tab)

  6. 6.

    Ankur G Kumardeep C Rahul K Sudheer G Harinder S RGP S Managing Drug Resistance in Cancer: Role of Cancer Informatics. Methods Mol Biol (Clifton NJ) (2016 ) 1395:299–312.

    Not in our library10.1007/978-1-4939-3347-1_17 (opens in a new tab)

  7. 7.

    Assaraf YG Brozovic A Gonçalves AC Jurkovicova D Linē A Machuqueiro M The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Update (2019 ) 46:100645.

    Not in our library10.1016/j.drup.2019.100645 (opens in a new tab)

  8. 8.

    M GM Orit L D HM Jean-Pierre G Toward a Better Understanding of the Complexity of Cancer Drug Resistance. Annu Rev Pharmacol (2016 ) 56:85–102.

    Not in our library10.1146/annurev-pharmtox-010715-103111 (opens in a new tab)

  9. 9.

    N AS Robert E R SE D SCM Fear of cancer recurrence: A qualitative systematic review and meta-synthesis of patients’ experiences. Clin Psychol Rev (2019 ) 68:13–24.

    Not in our library10.1016/j.cpr.2018.12.001 (opens in a new tab)

  10. 10.

    Pillay B Wootten AC Crowe H Corcoran N Tran B Bowden P The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev (2016 ) 42:56–72.

    Not in our library10.1016/j.ctrv.2015.11.007 (opens in a new tab)

  11. 11.

    Rogers MJ Matheson L Garrard B Maher B Cowdery S Luo W Comparison of outcomes for cancer patients discussed and not discussed at a multidisciplinary meeting. Public Health (2017 ) 149:74–80.

    Not in our library10.1016/j.puhe.2017.04.022 (opens in a new tab)

  12. 12.

    PhD IPD MB MPH CA MPH Kathleen M Castro RN MA Brandys B multidisciplinary treatment planning in US cancer care settings. Outcomes Cancer-Am Cancer Soc (2018 ) 124:3656–67.

    Not in our library10.1002/cncr.31394 (opens in a new tab)

  13. 13.

    Wyld L Audisio RA Poston GJ The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol (2015 ) 12:115–24.

    Not in our library10.1038/nrclinonc.2014.191 (opens in a new tab)

  14. 14.

    Schaue D McBride WH Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol (2015 ) 12:527–40.

    Not in our library10.1038/nrclinonc.2015.120 (opens in a new tab)

  15. 15.

    Stefan B Molecular precision chemotherapy: overcoming resistance to targeted therapies? Clin Cancer Res (2014 ) 20:1064–6.

    Not in our library10.1158/1078-0432.ccr-13-3194 (opens in a new tab)

  16. 16.

    Lee YT Tan YJ Oon CE Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol (2018 ) 834:28–32.

    Not in our library10.1016/j.ejphar.2018.07.034 (opens in a new tab)

  17. 17.

    Guo Q Huang F Goncalves C Rincón SVD Miller WH Translation of cancer immunotherapy from the bench to the bedside. Adv Cancer Res (2019 ) 143:1–62.

    Not in our library10.1016/bs.acr.2019.03.001 (opens in a new tab)

  18. 18.

    Fabian CJ Visvanathan K Somerfield MR Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update Summary. J Oncol Pract (2019 ) 15:607–10.

    Not in our library10.1200/jop.19.00379 (opens in a new tab)

  19. 19.

    AS S CM R TP T KP G BG M Helen B Clinical Development of Novel Drug-Radiotherapy Combinations. Clin Cancer Res An Off J Am Assoc Cancer Res (2019 ) 25:1455–61.

    Not in our library10.1158/1078-0432.ccr-18-2466 (opens in a new tab)

  20. 20.

    Linda H Cath T Magda Z Ross W Emma P James G Improving the effectiveness of cancer multidisciplinary team meetings: analysis of a national survey of MDT members’ opinions about streamlining patient discussions. BMJ Open Qual (2019 ) 8:e000631.

    Not in our library10.1136/bmjoq-2019-000631 (opens in a new tab)

  21. 21.

    Stone E Rankin N Kerr S Fong K Currow DC Phillips J Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study. Lung Cancer (2018 ) 124:199–204.

    Not in our library10.1016/j.lungcan.2018.07.032 (opens in a new tab)

  22. 22.

    Elena CM Romano D Corrado G Pietro I Alessandra E Massimo U Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Res TR (2019 ) 176:483–94.

    Not in our library10.1007/s10549-019-05261-5 (opens in a new tab)

  23. 23.

    Wu C Li M Meng H Liu Y Niu W Zhou Y Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China(Life Sci) (2019 ) 62:640–7.

    Not in our library10.1007/s11427-018-9461-5 (opens in a new tab)

  24. 24.
  25. 25.

    Wanqing Chen PhD MD RZ MPH PDB P BMedSc SZ Hongmei Zeng PhD MD PhD FB Cancer statistics in China, 2015. CA: A Cancer J Clin (2016 ) 66:115–32.

    Not in our library10.3322/caac.21338 (opens in a new tab)

  26. 26.

    Ma Y Zhou K Fan J Sun S Traditional Chinese medicine: potential approaches from modern dynamical complexity theories. Front Med-PRC (2016 ) 10:28–32.

    Not in our library10.1007/s11684-016-0434-2 (opens in a new tab)

  27. 27.
  28. 28.

    So T Chan S Lee V Chen B Kong F Lao L Chinese Medicine in Cancer Treatment - How is it Practiced in the East and the West? Clin ONCOL-UK (2019 ) 31:578–88.

    Not in our library10.1016/j.clon.2019.05.016 (opens in a new tab)

  29. 29.

    Nie J Zhao C Deng L Chen J Yu B Wu X Efficacy of traditional Chinese medicine in treating cancer (Review). Biomed Rep (2016 ) 4:3–14.

    Not in our library10.3892/br.2015.537 (opens in a new tab)

  30. 30.

    Liu J Mao JJ Wang XS Lin H Evaluation of Traditional Chinese Medicine Herbs in Oncology Clinical Trials. Cancer J (2019 ) 25:367–71.

    Not in our library10.1097/ppo.0000000000000404 (opens in a new tab)

  31. 31.
  32. 32.

    Liu X Li M Wang X Dang Z Yu L Wang X Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma. Phytomedicine (2019 ) 62:152930.

    Not in our library10.1016/j.phymed.2019.152930 (opens in a new tab)

  33. 33.

    Tang M Wang S Zhao B Wang W Zhu Y Hu L Traditional Chinese Medicine Proton vs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations. Med Sci Monitor (2019 ) 25:8430–7.

    Not in our library10.12659/msm.917251 (opens in a new tab)

  34. 34.

    Huang S Peng W Mao D Zhang S Xu P Yi P Kangai Injection, a Traditional Chinese Medicine, Improves Efficacy and Reduces Toxicity of Chemotherapy in Advanced Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. Evid-Based Compl Alt (2019 ) 2019:8423037.

    Not in our library10.1155/2019/8423037 (opens in a new tab)

  35. 35.

    Wong W Chen BZ Lee AKY Chan AHC Wu JCY Lin Z Chinese Herbal Medicine Effectively Prolongs the Overall Survival of Pancreatic Cancer Patients: A Case Series. Integr Cancer Ther (2019 ) 18:1534735419828836.

    Not in our library10.1177/1534735419828836 (opens in a new tab)

  36. 36.

    FuuJen T Xiang L ChaoJung C TeMao L JianShiun C PoHeng C Chinese herbal medicine therapy and the risk of overall mortality for patients with liver cancer who underwent surgical resection in Taiwan. Complement Ther Med (2019 ) 47:102213.

    Not in our library10.1016/j.ctim.2019.102213 (opens in a new tab)

  37. 37.

    Muenst S Läubli H Soysal SD Zippelius A Tzankov A Hoeller S The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med (2016 ) 279:541–62.

    Not in our library10.1111/joim.12470 (opens in a new tab)

  38. 38.

    Hongxing S Shih-Hsin YE Marty C John F Carlo C BJ A Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes Dis (2019 ) 6:232–46.

    Not in our library10.1016/j.gendis.2019.06.006 (opens in a new tab)

  39. 39.

    Andrews LP Yano H Vignali DAA Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol (2019 ) 20:1425–34.

    Not in our library10.1038/s41590-019-0512-0 (opens in a new tab)

  40. 40.

    Jinjing W Fanghua Q Zhixue W Zhikun Z Ni P Lei H A review of traditional Chinese medicine for treatment of glioblastoma. Biosci Trends (2020 ) 13:476–87.

    Not in our library10.5582/bst.2019.01323 (opens in a new tab)

All 104 references

Cited by papers we hold 1

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.